CAMBRIDGE, Mass. – December 1, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Results of ACE-011 studies will be presented at the following times and locations:
- “ACE-011, A SOLUBLE ACTIVIN RECEPTOR TYPE IIA IGG-FC FUSION PROTEIN, INCREASES HEMOGLOBIN AND IMPROVES BONE LESIONS IN MULTIPLE MYELOMA PATIENTS RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY: PRELIMINARY ANALYSIS” (Oral Presentation); Hall F, December 7th, 5:30 PM
-”RAP-011, A SOLUBLE ACTIVIN RECEPTOR TYPE IIA MURINE IGG-FC FUSION PROTEIN, PREVENTS CHEMOTHERAPY INDUCED ANEMIA” (Oral Presentation); Rooms 220-222, December 6th, 5:30 PM
-”MOLECULAR SEQUELAE OF ACTIVIN A-DEPENDENT OSTEOBLAST INHIBITION OF MYELOMA” (Poster Board I-811); Hall E, December 5th 5:30 PM
Results of ACE-536 studies will be presented at the following times and locations:
-”ACE-536, A NOVEL GDF-TRAP, PROMOTES RAPID INCREASE OF RED BLOOD CELLS IN VIVO IN AN EPO-INDEPENDENT MANNER” (Poster Board II – 482); Hall E, December 6th, 6:00 PM
-”ACE-536, A NOVEL GDF-TRAP, INCREASES HEMOGLOBIN, HEMATOCRIT, AND RED BLOOD CELLS IN RATS AND MONKEYS” (Poster Board III – 540); Hall E, December 7th, 6:00 PM
-”ADMINISTRATION OF A NOVEL GDF-TRAP PREVENTS ANEMIA INDUCED BY RENAL INSUFFICIENCY AND AUGMENTS RECOVERY FROM BLOOD LOSS” (Poster Board III – 973); Hall E, December 7th, 6:00 PM
About Acceleron
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-β superfamily of proteins. ACE-011 is currently being studied in two Phase 2 clinical trials in cancer patients. ACE-031 is currently being studied in a Phase 1 clinical trial in healthy volunteers and ACE-041 is being studied in a Phase 1 clinical trial in patients with advanced cancer. In addition, the company is developing several other new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase bone mass and strength. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com.
CONTACT:
Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development
Mariesa Kemble (Media)
Suda Communications LLC, 608-850-4745